Funded Grants

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons (MNs).

Most strokes occur from clots blocking vessels that supply blood flow to the brain.

While significant efforts have been made worldwide, the development of an effective therapy to significantly slow or halt ALS disease progression has remained elusive.

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the motor neurons degenerate, leading to symptoms of muscle weakness and progressive paralysis, resulting in the death of patients from respiratory failure.

Focused ultrasound (FUS) is a non-invasive, ground-breaking technique suggested for the treatment of Alzheimer’s disease (AD).

The abnormal accumulation of misfolded proteins and aggregates is the hallmark of multiple forms of ALS and other neurodegenerative diseases.

Stroke happens to 62,000 people each year in Canada.

The main aim of this project is to examine the efficacy of the non-pharmacological intervention of lower body negative pressure (LBNP) with head up tilt on cerebral blood flow and concussion symptoms during exercise in individuals with persisting symptoms.

The LINGO-1 protein is strongly associated with Alzheimer’s disease and is a novel drug target.